Harry Lampiris, MD

Professor of Clinical Medicine

Education
Post-Doc Fellow/Scholar, 1991 - School of Medicine, University of California, San Francisco
M.D., 1985 - School of Medicine, University of California, San Francisco
Residency, - School of Medicine, University of California, San Francisco
Websites
Publications

  1. Chien A, Domeracki S, Guntur S, Taylor K, Lu CM, Lampiris H, Blanc PD. Association between household exposure and cycle threshold in COVID-19 infected health care workers. 2021. PMID: 34348733


  2. Domeracki S, Clapp RN, Taylor K, Lu CM, Lampiris H, Blanc PD. Cycle Threshold to Test Positivity in COVID-19 for Return to Work Clearance in Health Care Workers. Journal of occupational and environmental medicine 2020. PMID: 32804748


  3. Ward LM, Peluso MJ, Budak JZ, Elicker BM, Chin-Hong PV, Lampiris H, Mulliken JS. Opportunistic coinfection with Pneumocystis jirovecii and Coccidioides immitis associated with idelalisib treatment in a patient with chronic lymphocytic leukaemia. BMJ case reports 2020. PMID: 32354764


  4. Budak JZ, Brickman CE, Abdoler EA, Wallender EK, Mulliken JS, Kerkhoff AD, Lampiris H, Babik JM, Koss CA, Schwartz BS. Response to: Is Burnout Infectious? Understanding Drivers of Burnout and Job Satisfaction Among Academic Infectious Diseases Physicians. Open forum infectious diseases 2020. PMID: 32284950


  5. Ramirez JA, Maddali MV, Budak JZ, Li JZ, Lampiris H, Shah M. Evaluating the Concordance of Clinician Antiretroviral Prescribing Practices and HIV-ASSIST, an Online Clinical Decision Support Tool. Volume 35 of Issue 5. Journal of general internal medicine 2019. PMID: 31792870


  6. Jehan Budak, Cristina Brickman, Emily Abdoler, Erika Wallender, Jennifer S Mulliken, Andrew D Kerkhoff, Harry Lampiris, Jennifer M Babik, Catherine Koss, Brian Schwartz, Brian Schwartz. 2534. Development of an Infectious Diseases Fellowship Well-Being Program. Open forum infectious diseases 2019. PMID:


  7. Yukl SA, Kaiser P, Kim P, Telwatte S, Joshi SK, Vu M, Lampiris H, Wong JK. HIV latency in isolated patient CD4+ T cells may be due to blocks in HIV transcriptional elongation, completion, and splicing. Science translational medicine 2018. PMID: 29491188


  8. Li P, Kaiser P, Lampiris HW, Kim P, Yukl SA, Havlir DV, Greene WC, Wong JK. Stimulating the RIG-I pathway to kill cells in the latent HIV reservoir following viral reactivation. Volume 22 of Issue 7. Nature medicine 2016. PMID: 27294875


  9. Louie JK, Lampiris H. Neuraminidase Inhibitors and Influenza Infection-Reply. Volume 176 of Issue 3. 2016. PMID: 26954054


  10. Louie JK, Lampiris H. Treating Influenza With Neuraminidase Inhibitors: What Is the Evidence? Volume 175 of Issue 12. 2015. PMID: 26501509


  11. Greene M, Covinsky KE, Valcour V, Miao Y, Madamba J, Lampiris H, Cenzer IS, Martin J, Deeks SG. Geriatric Syndromes in Older HIV-Infected Adults. Journal of acquired immune deficiency syndromes (1999) 2015. PMID: 26009828


  12. Chartier M, Crouch PC, Tullis V, Catella S, Frawley E, Filanosky C, Carmody T, McQuaid J, Lampiris H, Wong JK. The Montreal Cognitive Assessment: A Pilot Study of a Brief Screening Tool for Mild and Moderate Cognitive Impairment in HIV-Positive Veterans. Journal of the International Association of Providers of AIDS Care 2014. PMID: 25487428


  13. Greene M, Justice AC, Lampiris HW, Valcour V. Management of human immunodeficiency virus infection in advanced age. JAMA 2013. PMID: 23549585


  14. Ma Somsouk, Susie W. Ng, Rachel Kornfield, Kenneth R. McQuaid, Harry Lampiris, John M. Inadomi. Su1471 Colorectal Neoplasia in HIV-Infected Individuals During Screening and Surveillance Colonoscopy. 2012. PMID:


  15. Lampiris HW. Elvitegravir: a once-daily, boosted, HIV-1 integrase inhibitor. Volume 10 of Issue 1. 2012. PMID: 22149610


  16. Yukl SA, Li P, Fujimoto K, Lampiris H, Lu CM, Hare CB, Deeks SG, Liegler T, Pandori M, Havlir DV, Wong JK. Modification of the Abbott RealTime assay for detection of HIV-1 plasma RNA viral loads less than one copy per milliliter. Volume 175 of Issue 2. Journal of virological methods 2011. PMID: 21536073


  17. Hatano H, Hayes TL, Dahl V, Sinclair E, Lee TH, Hoh R, Lampiris H, Hunt PW, Palmer S, McCune JM, Martin JN, Busch MP, Shacklett BL, Deeks SG. A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. Volume 203 of Issue 7. The Journal of infectious diseases 2011. PMID: 21402547


  18. . CD4+ T cell reconstitution, T cell activation, and memory T cell subset composition in blood and gut of HIV-negative and ART-suppressed HIV-positive patients: implications for HIV persistence in the gut. 2010. PMID:


  19. . The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Volume 330 of Issue 6010. Science (New York, N.Y.) 2010. PMID: 21051598


  20. Yukl SA, Shergill AK, McQuaid K, Gianella S, Lampiris H, Hare CB, Pandori M, Sinclair E, Günthard HF, Fischer M, Wong JK, Havlir DV. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. Volume 24 of Issue 16. AIDS (London, England) 2010. PMID: 20827162


  21. Yukl SA, Gianella S, Sinclair E, Epling L, Li Q, Duan L, Choi AL, Girling V, Ho T, Li P, Fujimoto K, Lampiris H, Hare CB, Pandori M, Haase AT, Günthard HF, Fischer M, Shergill AK, McQuaid K, Havlir DV, Wong JK. Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. Volume 202 of Issue 10. The Journal of infectious diseases 2010. PMID: 20939732


  22. Hatano H, Lampiris H, Fransen S, Gupta S, Huang W, Hoh R, Martin JN, Lalezari J, Bangsberg D, Petropoulos C, Deeks SG. Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy. Journal of acquired immune deficiency syndromes (1999) 2010. PMID: 20300008


  23. Zolopa AR, Berger DS, Lampiris H, Zhong L, Chuck SL, Enejosa JV, Kearney BP, Cheng AK. Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial. Volume 201 of Issue 6. 2010. PMID: 20146631


  24. Cardenas VA, Meyerhoff DJ, Studholme C, Kornak J, Rothlind J, Lampiris H, Neuhaus J, Grant RM, Chao LL, Truran D, Weiner MW. Evidence for ongoing brain injury in human immunodeficiency virus-positive patients treated with antiretroviral therapy. Journal of neurovirology 2009. PMID: 19499454


  25. Fätkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, Hirschel B, Tebas P, Raffi F, Trottier B, Bellos N, Saag M, Cooper DA, Westby M, Tawadrous M, Sullivan JF, Ridgway C, Dunne MW, Felstead S, Mayer H, van der Ryst E, MOTIVATE 1 and MOTIVATE 2 Study Teams. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. Volume 359 of Issue 14. 2008. PMID: 18832245


  26. Shah T, Lampiris H, Vu M, Monto A, Tien PC. Resolution of hepatitis C virus-induced steatosis improves tolerability of antiretroviral drugs associated with hepatotoxicity in an HIV-infected individual. The Journal of infectious diseases 2008. PMID: 18419352


  27. Hunt PW, Brenchley J, Sinclair E, McCune JM, Roland M, Page-Shafer K, Hsue P, Emu B, Krone M, Lampiris H, Douek D, Martin JN, Deeks SG. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. Volume 197 of Issue 1. The Journal of infectious diseases 2008. PMID: 18171295


  28. Wong JK, Lampiris H. Covering all the bases: targeting HIV-1 integrase. Journal of acquired immune deficiency syndromes (1999) 2006. PMID: 17133210


  29. Hunt PW, Harrigan PR, Huang W, Bates M, Williamson DW, McCune JM, Price RW, Spudich SS, Lampiris H, Hoh R, Leigler T, Martin JN, Deeks SG. Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. Volume 194 of Issue 7. The Journal of infectious diseases 2006. PMID: 16960780


  30. Hunt PW, Deeks SG, Bangsberg DR, Moss A, Sinclair E, Liegler T, Bates M, Tsao G, Lampiris H, Hoh R, Martin JN. The independent effect of drug resistance on T cell activation in HIV infection. Volume 20 of Issue 5. AIDS (London, England) 2006. PMID: 16514299


  31. Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, Lampiris H, Deeks SG. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. Volume 187 of Issue 10. The Journal of infectious diseases 2003. PMID: 12721933


  32. Hare CB, Vu MP, Grunfeld C, Lampiris HW. Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2002. PMID: 12410494


  33. Schooley RT, Ruane P, Myers RA, Beall G, Lampiris H, Berger D, Chen SS, Miller MD, Isaacson E, Cheng AK, Study 902 Team. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS (London, England) 2002. PMID: 12045491


  34. Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Volume 34 of Issue 11. 2002. PMID: 12015695


  35. Donald C. Sheppard, Kathleen A. Bartlett, Harry W. Lampiris. Streptococcus pneumoniae Transmission in Chronic-Care Facilities: Description of an Outbreak and Review of Management Strategies. Infection control and hospital epidemiology 1998. PMID:


  36. Sheppard DC, Bartlett KA, Lampiris HW. Streptococcus pneumoniae transmission in chronic-care facilities: description of an outbreak and review of management strategies. Volume 19 of Issue 11. 1998. PMID: 9831942


  37. D. Colbom, H. Lampiris, B. Lee, R. Lewis, P. Sullam, P.K. Narang. Concomitant Cotrimoxazole (CTX) Does Not Affect Rifabutin (RBT) Kinetics in HIV+ Patients. Clinical Pharmacology & Therapeutics 1996. PMID: